chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Information has been received from a 62 year old female patient with phenobarbital allergy and none pertinent medical history. On 03-SEP-2015 the patient was vaccinated with ZOSTAVAX, subcutaneously (strength, dose and lot# were unknown) for vaccination. Concomitant therapies included ALLEGRA. On 04-SEP-2015, next morning the patient noticed that she had an injection site reaction. The injection site was bright red in color, extended about 3 inches and developed a rash. The rash extended from her shoulder to her elbow which became inflamed, including itching and pain (the pain lasted for five days). BENADRYL and CORTIZONE cream twice daily were given to treat the events. None lab diagnostics studies were performed. The patient reported this adverse reaction to her physician. The outcome of the events was reported as recovering/resolving. The causality was not reported. Additional information is not expected as there was no reporter's contacted information.
Patient complains of arm pain and rash. Explained possible side effects at time of injection. Patient sates arm is painful and slightly swollen with rash.
Information has been received from a pharmacist via a company representative, concerning an unspecified amount of patients of unknown age and gender. On unknown dates the patient was vaccinated with doses of ZOSTAVAX (subcutaneous, 0.65 ml, lot# and expiry date were not provided) and the patients experienced pain at the injection site during administration of ZOSTAVAX. The outcome of pain at the injection site was reported as recovered on unspecified dates. Additional information has been requested.
Low fever, swelling at size of 3" diameter and 3/4" deep, bright red color, extreme pain, fatigue, lethargy, all over body and joint ache.
DIFFICULTY BREATHING/HARD TIME BREATHING; COUGHING; CHEST PAIN; WHEEZING; This spontaneous report received from a parent concerned a 21 year old male. The patient's weight was 180 pounds, and height was 70 inches. The patient's past medical history included untreated pneumonia during childhood, and concurrent conditions included lungs not in great shape, no alcohol use, and no smoking, and other pre-existing medical conditions included the patient had not known any drug allergy. The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, intramuscular, batch number: 1802072, expiry: UNKNOWN) dose was not reported, administered on 20-MAR-2021 for prophylactic vaccination. No concomitant medications were reported. On 2021, the subject experienced wheezing. On 30-MAR-2021, the subject experienced difficulty breathing/hard time breathing. On 30-MAR-2021, the subject experienced coughing. On 30-MAR-2021, the subject experienced chest pain. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The patient had not recovered from difficulty breathing/hard time breathing, wheezing, coughing, and chest pain. This report was non-serious.
This spontaneous report was received from a licensed practical nurse and refers to an adult patient of unknown gender. No information regarding the patient's medical history, concurrent conditions or concomitant medications was provided. On 12-MAR-2018, the patient was vaccinated with a paediatric dose of VAQTA, strength: 25 U/0.5 ml, lot # N023953 with expiration date on 05-NOV-2018 via intramuscular route. No adverse events were reported.
Tingling of lips within hours of receiving shot, BP elevated to 185/92 for 24 hours receiving, bruising, itching and warm to touch.
Racing heart on 12/24/2021, PVCs continuing into 12/25/2021
8wks after receiving the vaccine she discovered a lump under her left arm. Soreness in the chest. Went to the dr and was dx with Hodgkin Lymphoma
Tested positive for covid-19 after receiving the first dose of the Pfizer covid-19 vaccine; Tested positive for covid-19 after receiving the first dose of the Pfizer covid-19 vaccine; Tired; A little bit of a headache; Sore throat; This is a spontaneous report from a Pfizer-sponsored program. A contactable consumer reported that a 55-years-old female patient received the first dose of the bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE, solution for injection) via an unspecified route of administration on left arm on 8Mar2021 at 11:00 as single dose for COVID-19immunization. Patient medical history and concomitant medication were not reported. Patient had tested positive for covid-19 after receiving the first dose of Pfizer Covid-19 vaccine, Patient had several COVID test done since 26Mar2021 and they have all been positive. Caller stated that she was tired and had a little bit of a headache and sore throat. It was stated that pulse oximeter is fine, showing 97-98%. Caller clarified and stated that she thinks these symptoms started Tuesday 23Mar2021 and on 25Mar2021 the patient was feeling perfect and those symptoms ended. on 26Mar2021 she thinks the PCR test was positive and COVID 19-antigen test was negative. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. The patient did not receive any treatment for the event. Outcome of the events tired, headache and sore throat was recovered while outcome of events drug ineffective and COVID-19 were unknown.  Information on the lot/batch number has been requested
I would just like to report that each time I took a covid shot, I started my period about 2-3 weeks after. the reason this is weird to me is because I am possibly infertile, I have PCOS. I do not ovulate, I have not had a period since 2017. Yet in 2021, I started my period after each injection. so this is not necessarily an adverse event, but I believe it could possibly be a side effect that should be reported. it seems too much of a coincidence that the only periods I've had since 2017 were in 2021 and each one after my vaccine.
tinnitus, i hear buzzing in my or ears or cricket  sound in my ears, it started about two weeks after the last covid  vaccine
patient received her booster dose on 10/25/2021 she recived 2.5 ml instead of 0.25 ml.
Patient received 3 doses of Hep A vaccine. No signs or symptoms or treatment needed.
Turned red and flushed within 5 minutes of vaccine administration.   Lasted for about 60 minutes.  No issues breathing.
Pt recvd 3 doses of vax & w/in hrs of 3rd dose exp nausea & elevated liver function tests;
I felt a pain shoot through my arm to my hand as I was being given the shot, then my arm and shoulder were very sore. I was unable to tolerate sleeping on my left side that night and I had a bad headache. My arm is still sore now but I can tolerate pressure on it better. Yesterday around 1:00 pm, the day after the shot, I began having some itching along the back of my neck near my hair line. By around 7:00 that night my neck continued to itch, I was not scratching however, but also my upper posterior neck into my hair line became red, hot, swollen, and painful. It spread equally across my posterior cervical spine from the base of my head to about C7 level (pics taken). My headache worsened and pain spread all the way down my spine to my lumbosacral region. I still have these symptoms now but to a lesser degree. I feel nauseated today as well and had to stay home from work and contact my doctor because of these symptoms.
Patient was given PCV 23 on 5/5/10 and developed blotchy rash 48 hours later surrounding injection site.
Red rash associated with hives over entire body and extremities. Treated with Benadryl elixir.
a 16 year old female patient, received the liquid component only of Menveo by error; a 16 year old female patient, received the liquid component only of Menveo by error; This case was reported by a other health professional via call center representative and described the occurrence of inappropriate preparation of medication in a 16-year-old female patient who received Men ACWY-CRM NVS (Menveo) (batch number AMVA748A, expiry date 30th November 2023) for prophylaxis.   On 7th November 2022, the patient received Menveo. On 7th November 2022, unknown after receiving Menveo, the patient experienced inappropriate preparation of medication and inappropriate dose of vaccine administered. On an unknown date, the outcome of the inappropriate preparation of medication and inappropriate dose of vaccine administered were unknown.   Additional Information: GSK receipt date: 08-NOV-2022 Reporters comment:  The patient received the liquid component only of Menveo vaccine by error.  Health Care Professional details were sent by email The reporter consent to follow-up. Additional Supportive information: Inadvertent administration of only the liquid Meningococcal CWY Component of Menveo to the patient, which led to inappropriate preparation of medication and inappropriate dose of vaccine administered.
An adult dose of Hepatitis A was given for the booster dose of Hep A - Should have been a pediatric dose.
Information has been received from a medical assistant (MA), via a company representative, concerning a 25 year old female patient, who on 14-NOV-2007 was vaccinated IM with the first dose of Gardasil (lot # not specified). Following the vaccination, the patient fainted. The patient recovered, and the MA noted that she was "fine before leaving the office." Additional information has been requested.
Information has been received from a healthcare worker concerning an unspecified number of patients of an unknown age and gender. Medical history and concurrent conditions were not reported. On an unknown date in 2015, "since 07-JAN-2015", the patients were vaccinated with improperly stored MMR II, lot # J006185, expired date as 24-MAY-2015: lot# J016234, expired date as 19-DEC-2015; lot# K003806, expired date as 13-MAR-2016; lot# K020188, expired date as 22-OCT-2016) (strengtth, dosage and route were not reported). No adverse effects were reported. This is one of several reports that received from the same reporter. Additional information has been requested.
Pt experienced light headedness, dizziness, loss of coordination and balance and fell to ground. Pt's mother said he was having a seizure, however when I saw pt, he was on ground outside of floor and seem disoriented. He was awake and said he was ok. Pulse was ok. Pt refused further treatment.
I tested positive for break through COVID-19 on 04/04/2022. I would think that my symptoms was classified mild. I had a severe headache, aches, pains, taste and smell. I still don't have my taste and smell. I also lost hair. I would get the tingling in my fingers, cough, congestions, no voice and fatigue. I had it for about 18 days.
Sore arm (days 1-5)?resolved on Day 5 Rash at injection site (days 5-7)?resolved on Day 7 Myalgia ? lasted 30 hours:  took Tylenol 1000 mg at 12 hr mark, took ibuprofen 600 mg at 24 hr mark. Resolved at 30 hr.  Swollen lymph node, right armpit (days 2-12)?resolved on  approx Day 12
Narrative:  83yo male patient w/ pmhx severeCOPD followed by outside pulmonary, CAD s/p PCI with stents followed by outside cardiology, colon CA s/p colon resection (2005) followed by GI in the past, HLD, HTN, anemia. Per last Primary care note in 7/2021 pt was at hospital in 4/2021 for GI bleed (ICU stay 10 days) and subsequent seizure-like activity, refused further testing. He has been in and out of hospitals over the past year for various problems (9 admissions since January 2020). At discharge in April 2021 pt was offered hospice as he had refused further testing. Wife reports that there are questionable diagnoses of liver cirrhosis and lung CA. No further notes since this time frame. Pt died on 10/12/2021.No info available. Pt had received a covid vaccine (J&J) on 4/9/2021 at hospital. This death is likely not related to the vaccinations due to comorbidities, age, and length of time from vaccine administration.
Swollen glands, swollen tongue, weakness, severe pain in mouth. went to theemergency room and was given pain killer and steroids
This spontaneous report was received from a registered pharmacist referring to a patient of unknown age and gender. Concurrent conditions or pertinent medical history were not reported. On 06-MAY-2015, the patient was vaccinated with an expired dose of ZOSTAVAX (lot # J012679 - Expiration date: 21-JAN-2015) (frequency was not reported), and no adverse symptoms were reported. Concomitant therapies were not reported. ZOSTAVAX was found to be supported with post-expiry in Company house data. Additional information has been requested.
Sever bodyaches, chills, low grade fever, fatigue less than 24 hours after getting COVID booster.  Patient had to rest and call into work due to body aches.
Swelling with 9 cm induration and 4cm x 6 cm area of firm,blistered red lesion at injection site.  Pt reports headache, racing heart beat, severe fatigue for 2 days.
Information has been reported in a study. This report concerns death events in adult ages 19 years and Older following PNEUMOVAX 23. The report includes US VAERS reports following PNEUMVOAX 23 or PPSV 23 brand unknown after 2002. The report includes reports information from 01-JAN-1990 to 31-JAN-2014. This spontaneous report as received from a registered nurse refers to 18 patients. The median age of the patients was 69 years old; range between 23 to 98 years. Between 01-JAN-1990 and 31-DEC-2013 patients were vaccinated with PNEUMOVAX 23. ON an unknown date the patients experienced death. The cause of death was reported as unknown. The death of the patients was confirmed with medical records, autopsy reports and/or death certificates. The report concerns death reports in adult ages 19 years and Older following PNEUMVOAX 23. The report has been split into cases according to cause of death. This case is linked to same reporter linked cases # 1406USA003857 (respiratory disorder), # 1406USA003858 (Other Infectious disorder), # 1406USA003859 (other non infectious disorder), # 1406USA003860 (gastrointestinal), # 1406USA003861 (Neurological), # 1406USA003862 (Undetermined) and # 1406USA003351 (Cardiovascular). Additional information has been requested.
Inflammed, tender, painful lymph nodes on right side of body, facial drooping, constant eye watering, difficult to close mouth and to speak clearly, challenging to shut eye.
This spontaneous report was received from a Licensed Practical Nurse refers to an unknown number of patients of unknown age and gender. No pertinent medical history was reported. On an unknown date, the patients were vaccinated with VAQTA (lot # L009445 and expiration date 01-JUN-2017) (dose and route were not reported) that had been improperly stored. No concomitant therapies were reported. No adverse effects reported. No Product Quality Complaint (PQC) was involved. This is one of the several reports from the same source. Additional information is not expected as the reporter did not wish further contact.
PATIENT CAME IN TO PHARMACY FOR A SHINGLE VACCINE ON 4/6/2017. SHE SHOWED NO SIGNS OF REACTION UNTIL THE MORNING OF 4/7/2017. PATIENT WORK UP WITH REDNESS, SWELLING AND HARDEN AND WARM TO  TOUCH AT THE SIGHT OF INJECTION. PATIENT CAME INTO PHARMACY ON 4/9/2017 TO REPORT REACTION. SHE SAID SWELLING RADIATED TO HER UNDER ARM. I ADVISED PATIENT TO SEEK  MEDICAL HELP AS SOON AS POSSIBLE AND TAKE BENADRYL AND USE ICE PAK IN THE MEANTIME.
The patient was given an expired rotatq on 3/27/2023. The vaccine expired 3/24/2023, the patient will not be harmed from this.
This spontaneous report as received from a 50 year old female consumer concerning herself. There was no pertinent medical history and no drug reactions/allergies. On 23-SEP-2013 the patient was vaccinated with ZOSTAVAX, (lot number and expiration date unknown), dose, route and anatomical location unspecified. Concomitant medications were not reported. On 23-SEP-2013, the patient reported that she had redness at the injection site on her left arm, it was hard, hot and itching and getting larger each day. The patient did not seek medical attention and no treatment was given. No lab diagnostics tests were performed. The outcome of redness at the injection site on her left arm and it was hard, hot and itching and getting larger each day was reported as not recovered/not resolved. Additional information is not expected.
Menveo administered without reconstitution; Menveo administered without reconstitution; This case was reported by a other health professional via call center representative and described the occurrence of inappropriate preparation of medication in a 14-year-old male patient who received Men ACWY-CRM NVS (Menveo) (batch number AMVA733A, expiry date 31st October 2023) for prophylaxis.   On 5th October 2022, the patient received Menveo. On 5th October 2022, unknown after receiving Menveo, the patient experienced inappropriate preparation of medication and inappropriate dose of vaccine administered. On an unknown date, the outcome of the inappropriate preparation of medication and inappropriate dose of vaccine administered were unknown.   Additional Information: GSK Receipt Date: 11-Oct-2022 Reporter's comment: The medical assistant reported that the patient received a dose of the liquid vial of Menveo without reconstitution with the powder.  The reporter consented to follow up. Additional Supportive Information: The patient received a dose of the liquid vial of Menveo without reconstitution with the powder, which led to inappropriate preparation of medication and inappropriate dose of vaccine administered.
3 days later I started bleeding vaginally and it was not time for my period and the bleeding lasted 45 days. I have never had a history of irregular or heavy cycles. I have always been consistent/on time and normal. Once that was over, my periods were extremely irregular for the net 6 months. One it got back to normal, it was only a 25-26 day cycle where I used to have 28-29 day cycles. The next day I was waking up and there was a noise in my head that coinsides with the movement of my eyes. Once I was fully awake it would go away. It was like a high pitched shooting noise that happens in the waking period. It lasted 2 years and its only just now starting to go away. Also experienced pshycological effects. Trouble with sleeping and memory, word finding. Psychological distress, anxiety and depression. Not diagnosed, that is just how I felt.
Dizziness; vomiting; This is a spontaneous report from a non-contactable consumer, the patient. A 22-year-old non-pregnant female patient received BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration on 13Apr2021 (at the age of 22-year-old) as a single dose for COVID-19 immunisation. Medical history included asthma. Concomitant medications included cetirizine (MANUFACTURER UNKNOWN) from an unknown date for allergy. The patient had no known allergies. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not take any other vaccine in four weeks. On 13Apr2021, the patient experienced dizziness and vomiting. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The patient did not receive any treatment for the reported event. The clinical outcome of the events dizziness and vomiting was unknown.   No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
fast heart beat from light activities; This spontaneous case was reported by a consumer and describes the occurrence of HEART RATE INCREASED (fast heart beat from light activities) in a 44-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 059e21a) for COVID-19 vaccination.     No Medical History information was reported.    On 28-Jul-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced HEART RATE INCREASED (fast heart beat from light activities). At the time of the report, HEART RATE INCREASED (fast heart beat from light activities) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.
A 14 year old female patient with a medical history of cerebral palsy and allergy to latex received a first injection of MENACTRA (lot number U2329AA) intramuscularly in the left deltoid on 14 February 2008. On 14 February 2008 the patient experienced ongoing bladder issues since she received the injection. The recovery status of the patient was unknown. No additional information was provided. Follow-up information was received from a health care professional on 20 August 2008. It was confirmed that the patient is male not female. On 14 January 2008, the patient experienced "bladder issues". Diagnosis was dysuria. Urinalysis was abnormal. CIPRO 250 mg, one tab twice daily times 10 days was prescribed. the patient was to return if there were concerns or if the condition worsened. Concomitant medications were BENZACLIN, DUAC and doxycycline monohydrate, all acne medications. On 14 February 2008, the patient had no complaints. Urinalysis results were reported as "normal, cloudy with trace protein". MENACTRA was administered on 14 February 2008. No further details concerning a post-vaccination adverse event were reported. Follow-up information was received form a health care professional on 26 September 2008, the reporter indicated that dysuria had been pre-existing in January 2008 and CIPRO was ordered on 14 February 2008 for 10 days. CIPRO stop date should have been 26 January 2008; the patient did not return to the office for the follow-up appointment. The patient had no concerns or complaints of dysuria during the office visit on 14 February 2008; a urinalysis on that date was cloudy with trace protein. The patient was seen twice after the MENACTRA injection and did not complain of any adverse events from the injection. It was reported that on 11 June 2008, the patient's mother asked for "Rx for bladder" but none was given and no tests were performed. It was also reported that on an unspecified date, the patient was referred to a specialist for urinary incontinence and persistent cerebral palsy.